Cell Bio Human Tech Co.,Ltd
Financials
Valuation Metrics
Cell Bio Human Tech Co.,Ltd's Market Cap is ₩586B. At end of 2025 it was ₩763B. Ranked #1628 of 2,436 in KR market (top 67%), #965 of 1,649 on KOSDAQ (top 59%), #192 of 294 in Materials (top 65%) by Market Cap.
Investment Metrics(as of 2026-08-04)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 58.64B KRW | KR#1,628/2,436 Sec#192/294 |
| Revenue | 55.53B KRW | KR#1,723/2,436 Sec#246/294 |
| Net Income | 9.14B KRW | KR#935/2,436 Sec#105/294 |
| Total Assets | 90.41B KRW | KR#1,828/2,436 Sec#251/294 |
| Net Assets | 61.21B KRW | KR#1,734/2,436 Sec#232/294 |
| Employees | 58 | KR#1,964/2,436 Sec#245/294 |
| Value | ||
| P/E | 6.41x | KR#419/2,436 Sec#44/294 |
| P/B | 0.96x | KR#1,452/2,436 Sec#231/294 |
| PEG | 0.20x | KR#521/2,436 Sec#64/294 |
| P/S | 1.06x | KR#1,431/2,436 Sec#226/294 |
| EV/EBITDA | 6.50x | KR#341/2,436 Sec#30/294 |
| FCF Yield | -8.78% | KR—/2,436 Sec—/294 |
| Profitability | ||
| ROE | 14.93% | KR#241/2,436 Sec#12/294 |
| ROA | 10.11% | KR#190/2,436 Sec#9/294 |
| Op. Margin | 16.76% | KR#222/2,436 Sec#10/294 |
| Revenue Growth | 53.80% | KR#277/2,436 Sec#16/294 |
| Earnings Growth | 32.37% | KR#675/2,436 Sec#87/294 |
| Financial Health | ||
| Debt Ratio | 147.70% | KR#1,156/2,436 Sec#151/294 |
| Total Debt | 20.58B KRW | KR#1,346/2,436 Sec#205/294 |
| FCF | -5.15B KRW | KR#1,504/2,436 Sec#181/294 |
| Cash | 18.70B KRW | KR#1,277/2,436 Sec#153/294 |
| Current Ratio | 2.43x | KR#772/2,436 Sec#79/294 |
| Net Debt/EBITDA | 0.20x | KR#716/2,436 Sec#63/294 |
| Performance | ||
| 1Y Return | -3.53% | KR#789/2,436 Sec#79/294 |
| 1M Return | 4.84% | KR#481/2,436 Sec#54/294 |
| From 52W High | -45.44% | KR#997/2,436 Sec#138/294 |
| 1Y MDD | -52.64% | KR#1,045/2,436 Sec#154/294 |
| Trading | ||
| Volume | 22,441 shares | KR#1,799/2,436 Sec#201/294 |
| Foreign Own. | 4.71% | KR—/2,436 Sec—/294 |
| Per Share | ||
| EPS | 994 KRW | KR#622/2,436 Sec#71/294 |
| BPS | 7,048 KRW | KR#1,179/2,436 Sec#177/294 |
Company Info
CellBioHumanTech was established in 2015 and listed on the KOSDAQ market in 2023. The company develops, manufactures, and supplies mask pack materials such as PT CELL, SEMI GEL, S Cell, and NC Cell, and is expanding into patches and wound dressings. It achieves cost savings and quality enhancement by directly producing non-woven fabrics at its Vietnam local subsidiary. CellBioHumanTech is expanding its global market presence through new material development and pursuing entry into the medical field with wound dressing development. CellBioHumanTech is headquartered in Anyang-si, Gyeonggi-do.